Skip to content
ATLAS PREP HQ
Cognitive

Cerebrolysin

Porcine brain-derived low-molecular-weight peptide and amino-acid mixture

Neurotrophic peptide mixture researched for neuroprotection, neuronal recovery, and cognitive function.

Limited Human Evidence

Route

Established international product: IM or IV infusion. Community research-vial page: subcutaneous. Do not assume equivalence.

Common format

60 mg vial

Research focus

stroke recovery

Evidence level

Limited Human Evidence

Typical cycle

10–30 days

Cognitive research motifCognitive

Cerebrolysin in 30 seconds

Atlas Fast Read

What it is

Porcine brain-derived low-molecular-weight peptide and amino-acid mixture

Why people care

Neurotrophic peptide mixture researched for neuroprotection, neuronal recovery, and cognitive function.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Uncertainty centers on which neurologic indications truly benefit, which patients respond, optimal dose/course, reproducibility across trial settings, and how evidence on the commercial IM/IV product maps to nonstandard lyophilized research products.

Bottom line

Cerebrolysin has more human data than many peptide-library entries, but results are indication-dependent and mixed.

Overview

What is Cerebrolysin?

Cerebrolysin is a porcine brain-derived mixture of low-molecular-weight peptides and amino acids rather than a single defined peptide. It has decades of clinical use in parts of Europe and Asia and has been studied for stroke, traumatic brain injury, dementia, and other neurologic conditions.

Cerebrolysin was developed as a porcine brain-derived neuropeptide preparation and has been used clinically in parts of Europe and Asia for decades. It has been studied in stroke, traumatic brain injury, dementia, and other neurologic conditions, with mixed trial results.

Mechanism

How it works

Contains low-molecular-weight peptides proposed to mimic or support neurotrophic signaling, reduce excitotoxicity and inflammation, and promote neuronal survival and plasticity. Because it is a mixture, no single receptor mechanism explains all reported effects.

Research areas

stroke recoverytraumatic brain injurydementianeuroprotection

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Cerebrolysin has a sizable human literature in stroke, dementia, and traumatic brain injury, including randomized trials and meta-analyses. Results vary by indication and study quality, so evidence is best considered mixed/limited rather than universally strong.

Preclinical evidence

Animal models show neurotrophic, anti-apoptotic, anti-inflammatory, and synaptic-plasticity effects after ischemia and neurodegeneration. Because Cerebrolysin is a mixture, mechanistic attribution is difficult.

Knowledge gaps

Uncertainty centers on which neurologic indications truly benefit, which patients respond, optimal dose/course, reproducibility across trial settings, and how evidence on the commercial IM/IV product maps to nonstandard lyophilized research products.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Important format caveat: clinical Cerebrolysin is a ready-to-use solution dosed in mL by IM/IV (often 5–30+ mL/day depending on indication). community sources separately lists a 60 mg lyophilized 'Cerebro Protein' research product at 20–32 mg/day SC; these products and dose units are not interchangeable.

Frequency

Clinical regimens are usually daily courses; the community research-vial protocol uses once or twice daily SC.

Timing

No universal time-of-day requirement.

Route

Established international product: IM or IV infusion. Community research-vial page: subcutaneous. Do not assume equivalence.

Cycle length

10–30 days

Reconstitution

Commercial Cerebrolysin is generally supplied as solution. the community 60 mg research-vial protocol uses 3 mL diluent for 20 mg/mL.

Storage

Follow the exact commercial/product label. Community sources list room-temperature lyophilized storage and refrigeration after reconstitution; commercial ampoules have different requirements.

Monitoring

Neurologic outcome scales, cognition/function, seizure history, renal status and adverse effects; monitoring depends heavily on indication and country-specific label.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Reported adverse effects include headache, dizziness, agitation, sweating, nausea and injection/infusion reactions; rapid administration can cause autonomic symptoms. Seizure risk and hypersensitivity are clinically relevant concerns.

Contraindications

International product information commonly lists hypersensitivity, epilepsy/seizure disorders and severe renal impairment as contraindications or major cautions; exact language varies by country/product.

Interactions

Caution is advised with antidepressants/MAO inhibitors in some product information because additive CNS effects are possible. Use should follow the exact commercial label and clinical context.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Cerebrolysin has more human data than many peptide-library entries, but results are indication-dependent and mixed. Atlas would also distinguish the established commercial IM/IV solution from vendor-marketed lyophilized 'Cerebro' products rather than treating them as interchangeable.

More in Cognitive

Cognitive

Adamax

Semax-derived nootropic research focused on BDNF signaling, neuroprotection, and cognitive performance.

Read guide

Cognitive

PE-22-28

Experimental TREK-1 antagonist peptide research focused on neuroplasticity and mood-related pathways.

Read guide

Cognitive

Pinealon

Short peptide bioregulator research focused on neuroprotection, cognition, and age-related brain function.

Read guide